Sovereign backs the MBO of private client trust and corporate services provider Aquitaine and its first two acquisitions Read more

  • Status: Current
  • Date: 2021
  • Sector:
    • Healthcare & Pharma Services
  • Buy & Build: 2

Back to Investments


Bioscript is a successful medical communications and regulatory writing agency for pharmaceutical companies. Sovereign has partnered with the management team to further develop and grow the business in this highly interesting and evolving market.

Investment Background

Bioscript was founded in 2005 by entrepreneur Andrew Medley. The business flourished and soon established itself as a successful international agency in the market. Keen to further develop the business, Andrew and the management team wanted to find an investment partner to support their growth ambitions for the business. The Sovereign team had followed Bioscript for over seven years and respected the company’s people and their ambitions. A deal was agreed.

Value Creation

  • At investment, Chris Brinsmead joined the team as non-executive Chair. Chris brings more than 30 years of Pharmaceutical experience, including an executive leadership role with AstraZeneca
  • The acquisition of Fortis Pharma Consulting
  • The acquisition of Valid Insight

The Story So Far

Bioscript is a successful global provider of medical communications and regulatory writing services for pharmaceutical companies. The business assists clients in their communications with regulatory authorities as well as educating the medical sector on pharmaceutical products that are in mid- to late-stage clinical trials and subsequently supporting these products, post market launch, to maintain and grow sales throughout the lifecycle of the drug.

Acquisitions to Date

Bioscript acquired two specialist global providers within 5 months of Sovereign's investment:

  • Fortis Pharma Consulting (, a medical affairs services provider that works with clients in refining and articulating a product’s value at launch
  • Valid Insight (, an award-winning market access consultancy that helps clients to deliver pricing, reimbursement, market access and payer value communication strategies through the full product development cycle

The Business Today

The acquisitions have strengthened Bioscript’s end-to-end service offering by extending the breadth and depth of its services across the pharmaceutical product lifecycle, and have brought additional capabilities in medical affairs, global market access strategy and payer value communications. The combined group has a staff of 135, which includes a large team of highly skilled specialist technical consultants and brings additional top 20 global pharma company clients.

Sovereign is working with the management team to further develop and grow the business.

Back to Investments


Since partnering with Sovereign, we have been delighted with the M&A opportunities the team have brought and helped us to transact. The acquisitions will enable us to build upon our extensive, integrated services at a time when increasing trial complexity, regulatory demands and pricing pressures require a fully joined-up, cross-functional approach.

Andrew Medley / Founder & CEO / Bioscript